Intravenous versus Oral Busulfan-Based Conditioning for Pediatric Allogeneic Hematopoietic Cell Transplantations: Did The Pendulum Swing Too Far, Too Fast?

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1657-1658

  Bredeson, Christopher ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; GRAFT FAILURE; HUMAN; LEUKEMIA REMISSION; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; MORTALITY; MYELOABLATIVE CONDITIONING; NOTE; OUTCOME ASSESSMENT; VEIN OCCLUSION; WHOLE BODY RADIATION;

BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING;

EID: 84887514928     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.008     Document Type: Note

References (13)

1. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia treatment after busulfan and cyclophosphamide. NEngl J Med 1983, 309:1347-1353.
2. Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994, 84:2036-2043.
3. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
4. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy withintravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 2002, 8:145.
5. Thall P.F., Champlin R.E., Andersson B.S. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs. other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2002, 33:1191-1199.
6. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral Busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic veno-occlusive disease (HVOD), HVOD related mortality and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493.
7. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
8. Geddes M., Kangarloo S.B., Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008, 14:220-228.
9. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity, and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000, 25:925-930.
10. Bredeson C, LeRademacher J, Kato K, etal. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood Epub ahead of print September 30, 2013; doi:10.1182/blood-2013-08-519009.
11. Nagler A, Rocha V, Labopin M, etal. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen-a report from the acute leukemia working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol Epub ahead of print August 26, 2013; 10.1200/JCO.2013.48.8114.
12. Rezvani R.R., McCune J.S., Storer B.E., et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 2013, 19:1033-1039.
13. Kato M., Takahashi Y., Tomizawa D., et al. Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation wit myeloablative conditioning regimens for pediatric leukemia. Biol Blood Marrow Transplant 2013, 19:1690-1694.